FibroGen Pretax Profit Margin from 2010 to 2024
| FGEN Stock | USD 1.12 0.03 2.75% |
Pretax Profit Margin | First Reported 2010-12-31 | Previous Quarter (1.94) | Current Value (1.84) | Quarterly Volatility 0.64862714 |
Check FibroGen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroGen main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.5 M, Interest Expense of 16.3 M or Selling General Administrative of 82.7 M, as well as many exotic indicators such as Price To Sales Ratio of 0.55, Dividend Yield of 0.0 or Days Sales Outstanding of 106. FibroGen financial statements analysis is a perfect complement when working with FibroGen Valuation or Volatility modules.
FibroGen | Pretax Profit Margin |
Latest FibroGen's Pretax Profit Margin Growth Pattern
Below is the plot of the Pretax Profit Margin of FibroGen over the last few years. It is FibroGen's Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in FibroGen's overall financial position and show how it may be relating to other accounts over time.
| Pretax Profit Margin | 10 Years Trend |
|
Pretax Profit Margin |
| Timeline |
FibroGen Pretax Profit Margin Regression Statistics
| Arithmetic Mean | (0.85) | |
| Coefficient Of Variation | (76.19) | |
| Mean Deviation | 0.54 | |
| Median | (0.50) | |
| Standard Deviation | 0.65 | |
| Sample Variance | 0.42 | |
| Range | 1.949 | |
| R-Value | (0.79) | |
| Mean Square Error | 0.17 | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | (0.11) | |
| Total Sum of Squares | 5.89 |
FibroGen Pretax Profit Margin History
About FibroGen Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include FibroGen income statement, its balance sheet, and the statement of cash flows. FibroGen investors use historical funamental indicators, such as FibroGen's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although FibroGen investors may use each financial statement separately, they are all related. The changes in FibroGen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on FibroGen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on FibroGen Financial Statements. Understanding these patterns can help to make the right decision on long term investment in FibroGen. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.94) | (1.84) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of FibroGen Correlation against competitors. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.